Low density lipoprotein screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [3]

Overview

According to the United States Preventive Services Task Force (USPSTF), screening for dyslipidemia, which includes high LDL-cholesterol (LDL-c), is indicated among men 35 years and older (Grade: A Recommendation), men 20 to 35 years old in case of an elevated risk for coronary heart disease (Grade: B Recommendation), women 45 years and older in case of an elevated risk for coronary heart disease (Grade: A Recommendation), and women 20 to 45 years old in case of an elevated risk for coronary heart disease (Grade: B Recommendation).^[1] There is insufficient evidence to recommend for or against screening for dyslipidemia among infants, children, adolescents, or young adults less than 20 years of age (Grade: I statement).^[1]

Screening

Screening Indications

Screening in Adults

Screening for dyslipidemia, including high LDL, depends on the gender, age, and the risk for coronary heart disease. Screening for dyslipidemia is indicated among the following:^[1]

Men 35 years and older (Grade: A Recommendation)
Men 20 to 35 years old in case of an elevated risk for coronary heart disease (Grade: B Recommendation)
Women 45 years and older in case of an elevated risk for coronary heart disease (Grade: A Recommendation)
Women 20 to 45 years old in case of an elevated risk for coronary heart disease (Grade: B Recommendation)

Screening in Children

There is insufficient evidence to recommend for or against screening for dyslipidemia among infants, children, adolescents, or young adults less than 20 years of age (Grade: I statement).^[1]

Screening Components

Screening for dyslipidemia includes:^[2]

Identification of risk factors for coronary artery disease
Estimation of the 10-year risk of cardiovascular disease
Measurement of fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 Screening for Lipid Disorders in Adults, Topic Page. U.S. Preventive Services Task Force. [1]
↑ Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW; et al. (2012). “American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary”. Endocr Pract. 18 (2): 269–93. PMID 22507559.

Template:WikiDoc Sources

[USPSTF-1] 1.0 ^1.1 ^1.2 ^1.3 Screening for Lipid Disorders in Adults, Topic Page. U.S. Preventive Services Task Force. [1]

[pmid22507559-2] Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW; et al. (2012). “American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary”. Endocr Pract. 18 (2): 269–93. PMID 22507559.

[1]

[2]